Ionis Pharmaceuticals Inc (NAS:IONS)
$ 38.27 -0.53 (-1.37%) Market Cap: 5.59 Bil Enterprise Value: 4.90 Bil PE Ratio: 0 PB Ratio: 18.85 GF Score: 70/100

Ionis Pharmaceuticals Inc at Citi BioPharma Conference Transcript

Sep 08, 2022 / 12:50PM GMT
Release Date Price: $44.27 (+1.89%)
David Neil Lebowitz
Citigroup Inc., Research Division - Research Analyst

So good morning, and welcome once again to the Citigroup 17th Annual Biopharma Conference. And I'm happy to have with me this morning from Ionis. If you could introduce yourselves to the crowd and maybe talk about the company's overall mission. It's a platform-based company with a powerful antisense platform.

Questions & Answers

Elizabeth L. Hougen
Ionis Pharmaceuticals, Inc. - Executive VP of Finance & CFO

Yes, absolutely. Eugene, you want to introduce first?

Eugene Schneider
Ionis Pharmaceuticals, Inc. - Executive VP & Chief Clinical Development Officer

Sure. My name is Eugene Schneider. I had clinical development at Ionis, and I've been there for about 9 years now.

Elizabeth L. Hougen
Ionis Pharmaceuticals, Inc. - Executive VP of Finance & CFO

And I'm Beth Hougen, I'm Ionis' CFO. I've been at the company for 22 years. So I've seen a lot of ups and downs and a lot of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot